Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Summary

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.

Timeline

Start

2017-12-21

Primary completion

2020-05-07

Completion

2020-05-07

Publications

• Maksimova K, Pustovalova M, Kuzmin DV, Leonov S, Merkher Y. Mapping metastatic potential through cytoskeletal remodeling: A mechanobiology-based multi-cancer analysis. Biochem Biophys Res Commun. 2026 Apr 9;808:153428. doi: 10.1016/j.bbrc.2026.153428. Epub 2026 Feb 14.
• Sever S. Role of actin cytoskeleton in podocytes. Pediatr Nephrol. 2021 Sep;36(9):2607-2614. doi: 10.1007/s00467-020-04812-z. Epub 2020 Nov 13.

Drugs

Indications